Linked Life Data

1884280

Source:http://linkedlifedata.com/resource/pubmed/id/1884280

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1991-10-9
pubmed:abstractText
Six horses gavaged with a commercial brodifacoum (BDF)-containing bait (Talone) at a dosage of 0.125 mg of BDF/kg of body weight showed weight loss, severe hypocoagulability and hemogram alterations. Four of the horses became depressed and anorectic; one required vitamin K1 therapy. Increases in clotting times were observed at 24 h in the partial thromboplastin time (PTT) followed by the thrombotest (TBT) and one-stage prothrombin time (PT) at 48 h. Elevated mean PTT, PT and TBT were observed from days 4 to 8 (p less than 0.05) with levels returning to pretreatment levels by day 12. Maximum prolongation was a fourfold increase in PTT (day 4), a 2.5-fold increase in TBT (day 6) and a twofold increase in PT (day 6). Thrombin clotting times remained unchanged. In two horses prolongation in clotting time did not normalize until day 23. The mean hematocrit (0.38 +/- 0.01 L/L) was decreased (p less than 0.05) from day 8 (0.33 +/- 0.02 L/L) to day 14 (0.33 +/- 0.01 L/L). The hemoglobin concentration and erythrocyte numbers were decreased (p less than 0.05) from day 6 (20.1%, 17.6% respectively) to day 14 (22%, 20% respectively). Platelet counts decreased on day 6 (17.2%) to nine (14.6%). No other significant changes were observed in routine hematological and serum biochemical parameters. Peak plasma concentrations of BDF occurred 2 to 3 h after oral administration; two horses had detectable levels of BDF at nine days. Pharmacokinetic evaluation indicated that BDF has a half-life of 1.22 +/- 0.22 days, a body clearance of 1073.1 +/- 53.21 mL/kg/day, a volume of distribution of 1853.7 +/- 26.41 ng-day/mL and closely approximates a one-compartment model in the elimination phase.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-14076133, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-17422277, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-2779175, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-3282375, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-3322522, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-3777660, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-3954219, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-4916914, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-6502864, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-6689111, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-6881659, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-7096182, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-7181945, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-7228793, http://linkedlifedata.com/resource/pubmed/commentcorrection/1884280-7236301
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0830-9000
pubmed:author
pubmed:issnType
Print
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21-7
pubmed:dateRevised
2010-9-10
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Clinical signs, laboratory changes and toxicokinetics of brodifacoum in the horse.
pubmed:affiliation
Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't